ORIGINAL ARTICLE | HEPATITIS C

Epidemiological, Clinical and Virological Characteristics of Patients with Hepatitis C in Morocco

Mohamed Rida Tagajdid, Pharm D1; Safae Elkochri, Pharm D1; Hicham Elannaz, MD, PhD1; Rachid Abi, MD1; Idriss Lahlou Amine, Pharm D1

1Department of Virology, Mohammed V Military Teaching Hospital, B.P: 10100, Hay Riad, Rabat, Morocco

Corresponding author email: tagajdid@gmail.com

ABSTRACT

Objectives: In Morocco, the exact and recent prevalence of Hepatitis C Virus (HCV) infection is not well-known due to the lack of recent epidemiological studies of the general Moroccan population. The objective of this study was to determine the prevalence of HCV and to describe the epidemiological, clinical and virological characteristics of patients infected with HCV diagnosed at the Mohammed V Military Teaching Hospital in Rabat, Morocco.

Methods: This was a prospective study, spread over a period of 3 years (April 2015 - April 2018). All patients with a positive anti-HCV serology were included in the study except those on hemodialysis. In addition to HCV serology, all patients included were tested with HIV serology as well as the Hbs antigen by a Chemiluminescent type Microparticle Immunoassay technique (Architect®, Abbott). RNA viral load and HCV genotyping were carried out using a real-time polymerase chain reaction.

Results: We collected 14,944 samples, of which 269 had positive anti-HCV antibodies (1.8%). The average age of patients with positive anti-HCV serology was 61 years, the sex ratio (Male/Female) was 1:4. Dental care was identified as the most common risk factor, (53% of the cases). Viral hepatitis C was identified in 82% of cases during a systematic check up. The main clinical signs reported in our series were asthenia (25% of cases) and subicterus (7% of cases).

Conclusion and Implications for Translation: In Morocco, the exact prevalence of HCV infection is not well known, due to the lack of recent epidemiological studies of the general Moroccan population. Our study showed a prevalence of about 1.8%, which is in accordance with the World Health Organization (WHO) estimation of between 1% and 2.49%. Our epidemiological study provides important information on the extent of the problem in Morocco, raises the interest in mass screening, and describes the populations at risk that will need to be identified as a priority.

Keywords: • Epidemiology • Diagnosis • Hepatitis C • Morocco • Risk factor • Military Hospital • Virology

Copyright © 2020 Tagajdid et al. Published by Global Health and Education Projects, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution License CC BY 4.0.
Hepatitis C in Morocco

1. Background and Introduction

The Hepatitis C Virus (HCV) belongs to the family of Flaviviridae. It is an enveloped virus whose genome is a single-stranded RNA. Seven genotypes and several subtypes of HCV have been identified. Transmission of the virus is mainly parenteral and the infection will be chronic in 80% of cases, which exposes patients to the risk of cirrhosis and hepatocellular carcinoma. Thus, hepatitis C is a major public health problem. The World Health Organization (WHO) estimates that 71 million people have chronic HCV. Over the past five years, the management of HCV infection has been revolutionized by the advent of direct-acting antivirals (DAAs). These drugs, which inhibit the action of some viral proteins, such as the NS3 and NS5A protease inhibitors and the NS5B polymerase, have brought good tolerance and almost constant efficacy. These therapeutic advances, as well as the significant morbidity and mortality from viral hepatitis, have motivated the establishment by WHO of a global strategy to combat viral hepatitis.

In Morocco, scattered studies report that seroprevalence of HCV in the general population varies between 0.41 and 1.12%. The objectives of this work were (1) to determine the prevalence of HCV in the population screened at the virology laboratory (Mohammed V Military Teaching Hospital, Rabat, Morocco), and (2) to describe the epidemiological and virological characteristics of patients infected by HCV.

2. Methods

2.1. Study Area

This was a prospective study carried out in the virology laboratory of the Mohamed V Military Instructional Hospital, spread over a period of 3 years (April 2015 - April 2018). All inpatients and outpatients with a positive “anti-HCV antibody” serology were included in the study. Hemodialysis patients affected by hepatitis C were excluded.

2.2. Study Design

The data were collected using a questionnaire comprise of the following items: last and first name, age, geographic origin, job, medical and surgical history, circumstances of HCV discovery, and other relevant facts.
initial symptomatology, and HCV risk factors. After informed, oral consent was obtained from each participant, we collected the data while respecting the anonymity of the patients.

2.3. Sampling and Data Analysis

During our study, we provided for all patients a dry tube for the detection of anti-HCV antibodies, HBs Antigen (HBsAg) as well as of the p24 Antigen and the anti-HIV antibodies 1 and 2 and two Ethylenediaminetetraacetic acid (EDTA) tubes for molecular biology tests (HCV RNA and genotyping). The samples were centrifuged for 20 min at 4000 rpm; the sera were stored at + 4 ° C; and the plasmas were stored at – 20°C. The investigation for anti-HCV antibodies was carried out by a Chemi-luminescent technique Microparticle Immunoassay (Architect®, Abbott) for hospitalized patients. HCV RNA viral load in blood was carried out using a real-time polymerase chain reaction (RT-PCR) on the Cobas Amplicrap/Cobas Taq Man (Roche®) for patients with positive HCV serology. HCV genotyping was carried out using Cobas® HCV GT kit on the Cobas 4800 (Roche®) for patients with viral load of >250 copies/ml. Other biological data were extracted from the laboratory Information System (Alanine amino-transferase (ALT)). Statistical analysis was performed using SPSS® software version 13.0 (IBM). The comparative study was carried out by the Chi-square test. A p-value of less than 0.05 was considered statistically significant.

3. Results

3.1. Sociodemographic Characteristics

We collected data for 14,944 samples of which 269 had positive anti-HCV antibodies which meant a seroprevalence of 1.8%. One hundred thirty two (0.88%) of these patients had a positive viral load which confirms current HCV infection. The average age of the patients was 61 years (28 – 95 years). Patients who were older than or equal to 50 years were the most affected by HCV. The 27-34 years and 35-49 years age groups were the least affected by HCV. No cases of HCV infection were found in patients younger than 24 years of age. Male predominance (58%) was noted with a sex ratio of Male/Female of 1:4. The majority of the patients with positive anti-HCV antibodies (36%) were retirees from the Royal Armed Forces of Morocco.

3.2. Hepatitis C Infection

The discovery of the HCV infection was fortuitous (during a systematic screening, proficiency visit or prenuptial check-up) in 82% of the cases. Twenty patients (7%) were referred by the transfusion center following the discovery of a positive anti-HCV serology. The symptomatic form was found in 12% of the cases. The most frequently reported clinical sign in our study was asthenia (6%) followed by jaundice (3%).

Diabetic and hypertensive patients represented 37% and 18% of patients with positive anti-HCV antibodies, respectively. Diabetes was more common in patients over the age of 50 years (p = 0.015).

3.3. Hepatitis C Risk Factors

A potential risk factor for HCV infection was identified in 92% of patients with positive anti-HCV serology. The most common risk factor was dental care (53%) and surgical history (28%). In addition, blood transfusion, dental care and surgical history have been strongly associated with the acquisition of HCV infection in patients over the age of 50 years (p <0.05) (Table 1).

3.4. Viral Load

A high viral load (≥800,000 IU/ml) was found in 136 cases or 51% of the patients. A medium (2,000 – 800,000 IU/ml) or low viral load (≤2,000 IU/ml) was found in 21 (7%) patients. A high initial viremia was significantly more frequent in male patients with an age greater than or equal to 50 years (p <0.05). A high viral load was strongly noted in patients with a history of surgery, transfusion or dental care (p <0.05). Undetectable viremia was found in 112 (42%) patients.

3.5. Genotyping

Genotyping was performed in 269 patients. Genotype 1b was predominant (80% of cases) followed by genotypes 2a/2c and 1a (7%). Genotype 1b was significantly more common in
men than in women and in patients with a high viral load (≥800,000 IU/ml) (p < 0.05). More than half of the patients (56%) with positive anti-HCV serology had an ALT level ≥ 2 to 3 times, mainly in men aged 50 years or over (p <0.05). In our study, only one case of HCV-HBV co-infection was diagnosed. No patient had a positive HIV serology.

4. Discussion

This was a single-center study carried out at the virology laboratory of the Mohammed V Military Teaching Hospital (MVMTH) and which concerned screening of 14,944 samples of which 269 patients has positive anti-HCV serology. The average age of patients with positive anti-HCV serology was 61 years. It is, therefore, an elderly population, which is consistent with published data in the literature. In our study, the advanced age of our patients could be explained by the nature of the population followed at the MVMTH, the latter being made up in large part of retired soldiers (33% in our series). Predominance of men has been reported with percentage up to 67%. In Morocco, the exact prevalence of HCV infection is not well known, due to the lack of recent epidemiological studies of the general Moroccan population. According to WHO data, the seroprevalence of HCV in Morocco varies between 1% and 2.49%. In our study, the seroprevalence of HCV was 1.8%. Benjelloun and colleagues reported that, in the general population, represented by parturient women and the military population, the seroprevalence of HCV was 1% and 0.5%, respectively. In another Moroccan study, where the general population was represented by people insured by the various national insurance funds, the seroprevalence of HCV varied from 0.9 to 1.2%. This rate remains close to that reported among Moroccan blood donors, which is 1.1%. The seroprevalence reported by our study remains lower than that reported in the Mediterranean region (2.4%) and close to that reported in the European region (1.5%).

In our study, viral hepatitis C was discovered in 82% of cases during a systematic assessment, in 11% of cases following a symptomatology, in 7%

Table 1: Distribution of Hepatitis C serological markers and principal risk factors in the study population

| Characteristic     | HCV Positive Subjects | HCV Negative Subjects | p-value |
|-------------------|-----------------------|-----------------------|---------|
|                   | N        | %       | N        | %       |         |
| Total: 14,944     | 269      | 1.8     | 14,675   | 98.2    |         |
| Age (years)       | <23      | 0       | 1,614    | 11.0    | p<0.05 (for patients aged 50 or over) |
|                   | 24-34    | 11      | 3,669    | 25.0    |         |
|                   | 35 – 49  | 43      | 7,924    | 54.0    |         |
|                   | ≥50      | 215     | 1,468    | 10.0    |         |
| Sex               | Female   | 113     | 5,723    | 39.0    | p=0.1   |
|                   | Male     | 156     | 8,952    | 61.0    |         |
| Dental care       | No       | 126     | 4,256    | 29.0    | p<0.05 (for patients aged 50 or over) |
|                   | Yes      | 143     | 10,419   | 71.0    |         |
| Blood transfusion | No       | 240     | 12,767   | 87.0    | p<0.05 (for patients aged 50 or over) |
|                   | Yes      | 29      | 1,908    | 13.0    |         |
| Surgical history  | No       | 194     | 6,017    | 41.0    | p<0.05 (for patients aged 50 or over) |
|                   | Yes      | 75      | 8,658    | 59.0    |         |
| Tattoos           | No       | 261     | 14,235   | 97.0    | p<0.3   |
|                   | Yes      | 8       | 440      | 3.0     |         |
of cases following a blood donation, and in 0.74% following a prenuptial check-up. In comparison, in Algeria, viral hepatitis C was discovered in 31% of cases following a systematic check-up, in 8% of cases following a prenuptial check-up, in 5% of cases following a blood donation, and in 28% of cases following symptomatology. In Tunisia, viral hepatitis C was discovered during a blood donation in 1.09% of cases. In France, hepatitis C was discovered in 46.2% of cases during a blood donation and in 56.8% of cases during a systematic assessment.

In the current study, transfusion was implicated in 11% of patients over the age of 50 years and in males (p <0.05). In a previous Moroccan study, this mode of transmission was identified in 21.7% of cases. The development of transfusion safety measures based essentially on serological techniques has made it possible to considerably reduce the risks of HCV transmission. Nevertheless, a residual risk, although very low, remains to this day due to the existence of a silent window, a period during which the serological markers systematically screened are not detectable. New molecular techniques have made it possible to envisage viral genomic screening. This approach ensures earlier detection of viral RNA in a subject carrying the virus. The use of these technologies in Morocco could detect DNA or RNA when the antigen/antibody serology tests may be negative.

Dental care was implicated in 53% of the cases. This factor was significantly linked to the acquisition of HCV infection in patients ≥ 50 years of age (p <0.05). A Maghrebian study has reported that this mode of contamination was suspected respectively in 24.7% of cases. For our study, this could be explained by the use in the past decade of non-sterile equipment for surgical procedures in situations of peacekeeping operations. The tattoo represents in our sample only a small proportion. This is probably the consequence of the significant regression of this habit due to a change in the conception of beauty and improvement in socio-cultural level. In some countries where tattooing is experiencing a renewed interest, this mode of HCV transmission was widely described (51% of cases in Canada). Furthermore, intravenous drug addiction generally constitutes a major mode of contamination with frequencies of up to 81% of cases according to studies carried out in Europe and Canada. In our study, no case of intravenous drug use was identified, which could be explained by the fact that drug addiction constitutes a taboo that is difficult to admit.

French studies have reported 20% of HIV-HCV co-infection; this high rate can be explained by the fact that the modes of transmission are similar, in particular in drug addiction and unprotected sex. The HCV-HIV association frequently reported in the literature was rare in our context, probably because drug addiction or unprotected sex were underreported in our context. The rate of HCV-HBV co-infections in our study was 0.4%. This may be explained by the systematic vaccination against hepatitis B of young military recruits and also by the awareness campaigns against sexually transmitted diseases at the level of military units. In our study, the most common genotype was 1b (80% of cases). In Morocco, the most common genotype is genotype 1, followed by genotypes 2 and 4.

Our study had some limitations. It was a single-center study. Access to clinical records was often difficult, making it impossible to analyze certain variables (virological response to treatment, histological data, adverse effects and resistance to treatment). Nevertheless, our study made it possible to describe the main epidemiological, clinical and virological characteristics of our study population. The aim is to better meet the WHO objective of eradicating this disease in 2030.

5. Conclusion and Implications for Translation

Viral hepatitis C is a major public health problem, on the one hand because of its frequency and on the other hand because of its complications with the risks of progression to cirrhosis and hepatocellular carcinoma. WHO has proposed a global strategy for the eradication of HCV in 2030. Faced with this international commitment to viral hepatitis (VH), Morocco has developed the first National Strategic Plan against VH for the period 2016-2021. The aim of this plan is to reduce the transmission of VH, as well as the mortality linked to VH by 30% and the prevalence of chronic HCV infections by 35% in 2021.
Hepatitis C in Morocco

with a view to eliminating HCV in Morocco in 2030. In this context, epidemiological studies are of major importance, since they provide a clear picture of the extent of the problem in our country. Our study promotes interest in mass screening and describes the populations at risk that will need to be identified as a priority. Prevention, in particular respecting the universal recommendations for the use of medical and paramedical equipment, as well as education and awareness-raising, are the best methods to halt the spread of this virus.

Compliance with Ethical Standards

Conflicts of interest: None. Financial Disclosure: Nothing to declare. Funding/Support: None. Ethics Approval: Ethics approval was not required for this study. Acknowledgments: None. Disclaimer: None.

Key Messages

► Mass screening with priority to people at risk can be a potential key for eradicating Hepatitis C Virus (HCV) in Morocco.
► In Morocco, viral genomic detection must be generalized with a view to eradication of HCV.
► Prevention measures, in particular in medical environment, as well as education are important to halt the spread of HCV.

References

1. World Health Organization. Rapport Mondial Sur l’hépatite (OMS). Geneva: WHO; 2017. http://apps.who.int/iris/bitstream/10665/255833/1/WHO-HIV-2017.06-fre.pdf?ua=1. Accessed April 14, 2020.
2. Fadlalla FA, Mohamoud YA, Mumtaz GR, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses. PLoS One. 2015;10(3):e0121873. doi: 10.1371/journal.pone.0121873
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirine dose. Ann Intern Med. 2004;140(5):346-355. doi: 10.7326/0003-4819-140-5-200403020-00010
4. Hatem C, Minello A, Martin L, et al.; REBOHC Research Group. Management of hepatitis C patients: a French population-based study. Gastroenterol Clin Biol. 2004;28(11):101-105. doi: 10.1016/s0399-8320(04)95188-3
5. Benjelloun S, Bennani A, Sekkat S, Benslimane A. Les hépatites virales au Maroc: aspect épidémiologique et moléculaire. Médecine et Armées. 2003;31:352-356.
6. Roth D. Hepatitis C virus: the nephrologist's view. Am J Kidney Dis. 1995;25(1):3-16. doi: 10.1016/0272-6386(95)90617-7
7. Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M. Prévalence de l’infection par le virus de l’hépatite C au Maroc et évaluation des tests sérologiques de dépistage pour la prédiction de la virémie. Pathol Biol. 2009;57(5):368-372. doi: 10.1016/j.patho.2009.07.001
8. Mallat A, DhumEAUX D. Les Marqueurs Non Invasifs de Fibrose Hépatique. Hépatite C. Paris: E.D.K, 2004:179-190.
9. Luma HN, Eloumou SAFB, Malongue A, et al. Characteristics of anti-hepatitis C virus antibody-positive patients in a hospital setting in Douala, Cameroon. Int J Infect Dis. 2016;45:53-58. doi: 10.1016/j.ijid.2016.02.013
10. DhumEAUX D. Surveillance et prévention des populations contre les Hépatites virales B et C en France. www. Santé-sports.gouv.Fr/pdf/planc — hépatite -2007. Accessed April 14, 2020.
11. Acharki M. benaissa A. Etude de la réponse à terme des patients atteints d’hépatite virale d’hépatite virale C traités par bithérapie. Thèse de médecine, Rabat; 2002.
12. Busch MP, Lee L, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion. 1995;35:91-7.
13. Laperche S. Réflexions concernant le dépistage des acides nucléiques des virus des hépatites B et C et du virus de l’immunodéficience humaine dans la qualification biologique des dons. Trans Clin Biol. 1998;5:139-46.
14. Hatem C, Minello A, Martin Land al. Management of hepatitis C patients: a French population-based study. Gastroentérologie Clinique et Biologique. 2004;28:1101-1105.
15. Facteurs de risque pour l’hépatite C: analyse
des enquêtes épidémiologiques faites lors de la déclaration des cas d’infection par le VHC au Québec: avril 2002 à mars 2004.

16. Zaied A, Elneihoum A, Elzouki A. Routine screening for anti-HIV antibodies, hepatitis B surface antigen and anti-hepatitis C antibodies among general hospital in-patients. *Jamahiriya Med J*. 2010:8–21.

17. Cacouba P, Rosenthalb E. Mono-infection par le virus de l’hépatite C et co-infection par le virus de l’immunodéficience humaine et le VHC: analyse comparative de la prise en charge à partir de deux larges enquêtes française récentes. *La revue de médecine interne*. 2012;33(7):355-357.

18. Baha W, Foullous A, Dersi N, et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. *BMC Public Health*. 2013;13:50. doi: 10.1186/1471-2458-13-50.